Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections

Diabetic Foot Infections Clinical Trial

Official title:
An Open-Label, Single-Arm, Multi-Center Study of TG-873870 for Treating Patients With Diabetic Foot Infections of Mild to Moderate Severity Associated With Gram-Positive Pathogens

Status Completed

Clinical Trial Summary

Clinical Trial Description

This study will assess the safety and efficacy of TG-873870 (Nemonoxacin) in patients with Diabetic Foot Infections. Pharmacokinetic (PK) and pharmacodynamic (PD) assessment will be conducted in a subgroup of eight consenting patients. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00685698
Study type	Interventional
Source	TaiGen Biotechnology Co., Ltd.
Contact
Status	Completed
Phase	Phase 2
Start date	June 2008
Completion date	June 2009

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06232421` - Clinical Study in Adult Patients With Purulent-inflammatory Processes of the Skin and Soft Tissues, Phase I-II of the Wound Process	Phase 2/Phase 3
Completed	`NCT00737269` - A Complicated Skin and Soft-tissue Infection Patient Registry	Phase 4
Terminated	`NCT01539811` - Diabetic Foot Infection Antibiotic Study	N/A
Completed	`NCT02737722` - Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus	Phase 1/Phase 2